Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume 162, Issue -, Pages 138-147
Publisher
Elsevier BV
Online
2022-01-05
DOI
10.1016/j.ejca.2021.11.019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.
- (2020) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
- (2020) S. Rao et al. ANNALS OF ONCOLOGY
- 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
- (2020) S. Lonardi et al. ANNALS OF ONCOLOGY
- 403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
- (2020) V. Morris et al. ANNALS OF ONCOLOGY
- Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
- (2020) Laurie Spehner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal
- (2019) Angélique Saint et al. Cancer Medicine
- Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer
- (2019) Elodie Lauret Marie Joseph et al. Cancer Immunology Research
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
- (2018) Stefano Kim et al. LANCET ONCOLOGY
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
- (2017) Van K Morris et al. LANCET ONCOLOGY
- Platinum‐Fluoropyrimidine and Paclitaxel‐Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients
- (2017) Francesco Sclafani et al. ONCOLOGIST
- Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer
- (2014) Richard Kim et al. ONCOLOGY
- DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma
- (2013) S. Kim et al. ANNALS OF ONCOLOGY
- Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
- (2012) M. Dosset et al. CLINICAL CANCER RESEARCH
- Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study
- (2010) Laurent Abramowitz et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation